NEU GRAND LIBRARY
Opening Hours: Monday-Saturday, 08:00-20:00 | E-mail: library@neu.edu.tr
 

You are not logged in Show Basket
  Home     Advanced Search     Back  
Print
Add to Basket
  Brief display     MARC Display     Reserve  
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia (Kurt, M.)
Bibliographical information (record 264319)
Help
Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia
Author:
 Kurt, M. Search Author in Amazon Books

Publisher:
Wiley-Liss,
Edition:
 2005.
Classification:
 WH 100.3
URL:
http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.1002/ajh.20432
Detailed notes
    - Gemtuzumab ozogamicin (GO; CMA-676; Mylotarg((TM))) is a chemotherapeutic agent approved for the treatment of CD33-positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno-occlusive disease has been reported to develop as a late complication of gemtuzumab ozogamicin treatment. A patient who developed Budd-Chiari Syndrome with hepatic vein thrombosis following treatment with GO is presented. This complication has not been previously reported, and it deserves to be considered as a possible adverse effect of gemtuzumab ozogamicin.
Related links
Items (1)
Barcode
Status
Library
Section
EOL-87
Item available
NEU Grand LibraryOnline (WH 100.3 .P67 2005)
Online electronic
NEAR EAST UNIVERSITY GRAND LIBRARY +90 (392) 223 64 64 Ext:5536. Near East Boulevard, Nicosia, TRNC
This software is developed by NEU Library and it is based on Koha OSS
conforms to MARC21 library data transfer rules.